Vaginal Mesh Lawsuit

October 2025: New Sparc Sling Mesh Lawsuit

A new lawsuit was filed in the U.S. District Court for the Central District of Illinois by a woman from Tolono who alleges she suffered serious injuries from the Sparc Sling System, a pelvic mesh product manufactured by American Medical Systems and its parent company, Endo Pharmaceuticals. The plaintiff underwent implantation of the device in July 2020 and later endured severe complications, including mesh erosion and the need for corrective surgery in January 2024.

The lawsuit brings claims for negligence, strict liability for design and manufacturing defects, failure to warn, and fraudulent concealment. The plaintiff alleges that the Sparc Sling was defectively designed using polypropylene and collagen components that are biologically incompatible with human tissue, resulting in chronic inflammation, pain, and permanent injuries.

She further asserts that the defendants failed to disclose known risks to patients and physicians and instead marketed the product as safe and effective for treating stress urinary incontinence and pelvic organ prolapse, despite mounting evidence and regulatory warnings suggesting otherwise.

September 2025: What a Transvaginal Mesh Lawsuit Is Really About

At its most basic, a transvaginal mesh lawsuit is about compensation. That is how civil cases work. A person is injured, and the legal system assigns money to that harm. Our lawyers do not run from the fact that this is our job: maximizing settlement compensation for victims.

But for many women, it is about something else, too. In depositions, lawyers have uncovered internal documents showing mesh manufacturers were hearing complaints about mesh tension and erosion as far back as 2009. Doctors flagged these issues, but they were not shared with regulators. And they were not in the materials patients saw before surgery.

That matters because many women were told their symptoms were unrelated, that their pain was normal, or that they were simply getting older. Some were told it was in their head. These cases are not just about science or medicine. They are about credibility. For many women, the question is not only, “What is my case worth?” but also, “Is someone finally going to acknowledge what happened?”

September 2025: State Court Filings Continue to Rise

Plaintiffs’ lawyers continue to file new standalone pelvic mesh cases in state courts, particularly in New Jersey for Ethicon cases and Massachusetts for Boston Scientific cases. These filings are outside the closed federal MDLs and are moving on individual scheduling tracks.

For victims, this means faster discovery, earlier trial settings, and more leverage for case-specific settlements.

September 2025: UK Five-Year Mesh Complications Study

A major observational study from a pelvic mesh referral center reviewed data on 785 women treated between 2018 and 2023.

The study found that 92% reported pain alone, and 58% opted for surgical management, with over half requesting full mesh removal. While only 0.7% experienced serious surgical complications, a 66% recurrence rate of stress urinary incontinence after treatment was noted. The study highlights the prevalence and severity of mesh-related pain and the continuing need to understand and address these complications.

September 2025: Targeted Settlement Mediation Programs Expand

Several courts overseeing individual mesh dockets have broadened their mediation programs, appointing neutral mediators and setting rolling settlement conferences. The focus is on cases with multiple revisions, documented mesh erosion, and chronic pelvic pain. These programs are designed to resolve groups of cases without delaying those that are trial-ready.

For plaintiffs, this is welcome news. Strong and well-documented transvaginal mesh cases are seeing more individualized negotiations.

August 2025: Ethicon Lawsuit in New Jersey

A plaintiff in New Jersey state court is pursuing claims against Ethicon over a pelvic mesh implant that allegedly caused long-term injuries. A new scheduling order requires expert disclosures and closes discovery on a short timeline.

This lawsuit is part of a growing wave of standalone state court cases that target mesh manufacturers outside the scope of MDL settlements. These state filings are increasingly preferred because they can move faster and give plaintiffs a more individualized path toward trial.

July 2025: Recent Settlements

Despite mass settlements in the federal MDLs, new transvaginal mesh cases are still being filed in state courts across the country. Many of these cases target Coloplast and Boston Scientific over newer injuries or recent revision surgeries.

Settlements in standalone cases are trending higher than many of the earlier bulk MDL settlements. For strong current claims, our lawyers generally evaluate settlement potential in the $150,000 to $900,000 range, depending on product identification, revision surgery, chronic pain, erosion, organ involvement, and the strength of the medical records. Older MDL bulk settlements were often much lower because strong and weak cases were grouped together.

June 2025: New Study Links Polypropylene Mesh to Autoimmune Disorders

A peer-reviewed study found evidence that polypropylene particles from transvaginal mesh implants can trigger autoimmune and inflammatory responses, including symptoms consistent with Autoimmune/Inflammatory Syndrome Induced by Adjuvants, sometimes called ASIA.

This research may have legal implications because it supports claims that manufacturers failed to disclose long-term risks associated with systemic immune reactions. Plaintiffs’ attorneys are already referencing this data in ongoing litigation against Coloplast, Ethicon, and Boston Scientific.

The study adds to the growing body of evidence that pelvic mesh complications may extend beyond localized pain or erosion and may involve systemic inflammatory dysfunction.

May 2025: New Coloplast Lawsuit

A Tennessee woman sued Coloplast Corp. in Hennepin County, Minnesota, alleging injuries caused by the company’s Aris transobturator sling system. The plaintiff claims she suffered serious and permanent injuries after being implanted with the Aris device, a pelvic mesh product intended to treat stress urinary incontinence.

The complaint asserts that Coloplast marketed and distributed the Aris mesh despite knowing that its primary material, non-absorbable polypropylene, is biologically incompatible with human tissue. The plaintiff alleges that the mesh caused a severe foreign body reaction, leading to chronic inflammation, pain, nerve damage, urinary dysfunction, and sexual complications.

Filed in Minnesota’s Fourth Judicial District, the complaint emphasizes that Coloplast’s device was cleared through the FDA’s 510(k) process, which does not require the same proof of safety and efficacy as full premarket approval.

May 2025: Why Minnesota and Massachusetts?

Minnesota and Massachusetts have become key battlegrounds for these cases. Coloplast is based in Minnesota, and Boston Scientific is headquartered in Massachusetts. Filing in those states can keep cases in state court because a defendant generally cannot remove a case to federal court based on diversity jurisdiction when sued in its home forum.

State courts can provide a better path for some plaintiffs. Compared with federal MDLs, state court cases may move faster, give more control to individual plaintiffs, and allow local juries to decide individual claims.

April 2025: Why Larger Settlements Now Than Before?

Standalone vaginal mesh lawsuits may produce higher settlements than older MDL inventory settlements because the best cases are being filed individually. That allows for personalized evidence, individualized damages, and greater jury sympathy.

MDLs can be efficient, but global settlements often average out payouts. In contrast, standalone cases with trial dates force defendants to negotiate more seriously to avoid the risk of large jury verdicts.

February 2025: Pre- and Post-Market Failures

The bladder sling crisis did not arise overnight. Plaintiffs allege it resulted from failures before the products reached the market and after they were already being used in patients.

Manufacturers did not conduct the rigorous testing these products required. Many vaginal mesh devices were cleared through the FDA’s 510(k) process, which allowed them to bypass extensive clinical trials based on similarity to existing devices. The flawed assumption was that mesh materials used for hernia repairs would function just as safely in the pelvic floor, despite the anatomical and functional differences between those areas.

Even after mesh was widely used, plaintiffs allege manufacturers and regulators failed to adequately monitor and respond to emerging problems. Adverse events such as mesh erosion, organ perforation, chronic pain, inflammation, and permanent injury were either underreported or not addressed quickly enough.

For women pursuing vaginal mesh lawsuits, these failures form the foundation of many claims. The litigation is not just about compensation. It is also about accountability for women who were told these products were safe and then suffered life-altering injuries.

January 2025: Settlement Talks

We have received reports that some defendants are approaching individual law firms to settle inventories of transvaginal mesh lawsuits. We will update this page as more concrete information becomes available.

January 2025: Defense Verdict in Pelvic Mesh Malpractice Case

A jury in Oregon issued a defense verdict in a case accusing a urologist and hospital of medical malpractice for implanting a pelvic mesh device. The plaintiff alleged the doctor and hospital were negligent for failing to obtain informed consent before implanting Boston Scientific’s Uphold Lite mesh device to treat pelvic organ prolapse.

This was a medical malpractice case, not a product liability case against the manufacturer. Informed consent malpractice cases can be difficult to win, so the defense verdict is not surprising.

2024 and Older Updates

December 2024: New Study on Design Flaws in Vaginal Mesh Materials

A newly published study found that many vaginal and pelvic mesh implants may have been destined for failure because of significant flaws in design and manufacture. The study, conducted by researchers from the University of Sheffield, found that the plastic material used in many vaginal mesh implants can begin to degrade shortly after implantation.

October 2024: New Study on Polypropylene Mesh Degradation

A new study examined how polypropylene mesh degrades over time after implantation, focusing on surface and structural changes.

The study found that after 60 and 180 days of implantation, polypropylene mesh underwent significant changes that could create problems for patients. Researchers found surface degradation, oxidation, and particle shedding into surrounding tissue. By 180 days, cracks appeared, the mesh stiffened, and more particles were released.

These particles can contribute to inflammation. The longer the mesh remains in the body, the more significant the degradation may become. For plaintiffs, the study supports the argument that polypropylene mesh used in pelvic surgeries is not as stable or biocompatible as manufacturers claimed.

October 2024: Study on the Human Impact of Transvaginal Mesh Complications

In a new study, researchers examined the pain and complications faced by women with pelvic or vaginal mesh implants, as well as the psychological effects of those complications. The study reviewed qualitative research in which women described their experiences through interviews and written accounts.

Four major themes emerged. Women described chronic pain and serious disruption to their bodies and daily lives. Many lost trust in doctors and the medical industry after years of feeling dismissed or unsupported. The study also highlighted emotional and social struggles, including isolation, relationship strain, and the frustration of trying to make physicians understand the seriousness of their symptoms.

For plaintiffs, this kind of research matters because it explains what medical records alone often fail to capture. Mesh complications are not just mechanical failures. They can change how women move, work, have sex, trust doctors, and live their lives.

October 2024: FDA Issues Updated Safety Notice on Transvaginal Mesh

The FDA updated its safety guidance concerning transvaginal mesh products, reiterating that patients and healthcare providers should carefully consider alternative treatments for pelvic organ prolapse and stress urinary incontinence. Although most transvaginal mesh devices for pelvic organ prolapse were removed from the market in 2019, the agency emphasized the importance of continued patient monitoring and raised concerns about long-term complications from previously implanted devices.

August 2024: Another Transvaginal Mesh Lawsuit in Minnesota State Court

An Alabama woman filed a lawsuit in Hennepin County, Minnesota, against Coloplast A/S, Coloplast Corporation, and Coloplast Manufacturing U.S., LLC, alleging injuries caused by the company’s pelvic mesh products.

The plaintiff underwent surgery to implant Coloplast’s Altis Single Incision Sling and Restorelle products in 2019 to treat stress urinary incontinence and pelvic organ prolapse. She claims the devices caused severe complications, including chronic pain and the need for corrective surgery.

The lawsuit accuses the defendants of negligence, strict liability, breach of warranties, fraud, and violations of Minnesota consumer protection laws. The plaintiff alleges the company knew or should have known about the risks associated with the mesh products but failed to adequately warn patients and healthcare providers.

July 2024: New Vaginal Mesh Lawsuit in Massachusetts

In a pelvic mesh lawsuit against Boston Scientific filed in federal court in Massachusetts, the plaintiff seeks damages for injuries allegedly caused by a defective sling.

The plaintiff underwent a medical procedure to address stress urinary incontinence and pelvic pain, including implantation of the Obtryx II Transobturator Mid-Urethral Sling System. Following surgery, she began experiencing severe pain, which worsened over time. She and her doctors eventually suspected that the pelvic mesh was the source of her symptoms.

The plaintiff experienced vaginal dryness, right-sided pelvic pain, painful sexual intercourse, bladder spasms, and stress incontinence. She required further medical intervention, including revision surgery to adjust the tension of the implanted sling.

July 2024: Federal Appeals Court Reinstates Transvaginal Mesh Lawsuit

A federal appeals court reinstated transvaginal mesh lawsuits after the West Virginia Supreme Court clarified the burden of proof for design defect claims.

The Fourth Circuit ruled that the federal trial court improperly restricted the couple’s expert testimony. The expert needed to show that alternative feasible designs could substantially reduce the injury risk, not eliminate it entirely.

June 2024: Court Upholds $2.5 Million Verdict

The Eleventh Circuit upheld a $2.5 million verdict against Coloplast Corp. in a lawsuit alleging that a woman was implanted with defective pelvic mesh.

The key issue was whether the plaintiff met the deadline to file a vaginal mesh lawsuit. The court rejected Coloplast’s argument that the claim was filed too late, noting that earlier symptoms were not enough to alert her that the mesh was defective. More severe symptoms in 2014 started the clock, keeping the case within Florida’s four-year statute of limitations.

June 2024: Study Examines Complications Associated With Mid-Urethral Sling Surgery

A new study examined risk factors for complications within five years after mid-urethral sling surgery for stress urinary incontinence. The study reviewed records from 1,961 women who underwent their first mid-urethral sling surgery between 2003 and 2018.

The study identified risk factors for surgical complications, including secondary surgery and urinary retention. These findings suggest doctors and manufacturers should consider individual patient histories when recommending and implementing mesh devices.

February 2023: Study Compares Robotic Sacrocolpopexy with Transvaginal Mesh Surgery

A study compared robotic sacrocolpopexy and transvaginal mesh surgery in women with pelvic organ prolapse. The study found that women who underwent robotic sacrocolpopexy were more likely to experience new stress urinary incontinence compared to those who had transvaginal mesh surgery.

Both groups saw improvement in some symptoms, including difficulty voiding and urine retention, but the robotic sacrocolpopexy group had a significant increase in stress incontinence.

January 2023: Study Finds Many Women Experienced Improved Sexual Function Following POP Surgery

A study found that many women experienced improved sexual function after pelvic organ prolapse surgery using transvaginal mesh. The study was small, involving 48 women, so it is not conclusive. But it provides some context for how outcomes can vary depending on the patient, procedure, and product.

October 2023: Aftermath of the 2015 Boston Scientific Settlement

In June 2015, Boston Scientific agreed to a transvaginal mesh settlement with 1,200 victims for approximately $53 million. The average mesh settlement was about $44,000.

An independent special master oversaw the distribution of funds. Each claimant’s amount was determined using a point allocation formula based on severity of complications and required surgeries. Years later, two women filed a lawsuit against their attorneys, alleging mishandling of their claims and coercion into settlement. The court ruled that the claims were time-barred.

September 2023: Boston Scientific Settles Georgia Federal Court Lawsuit

Boston Scientific settled a lawsuit in Georgia federal court involving allegations related to its Obtryx pelvic mesh product. The plaintiff claimed that the mesh caused chronic pain and nerve damage. The settlement terms were not disclosed.

July 2023: New Jersey Supreme Court Addresses McGinnis v. C.R. Bard, Inc.

In McGinnis v. C.R. Bard, Inc., the New Jersey Supreme Court addressed whether Bard was denied a fair trial by not being allowed to present FDA 510(k) clearance evidence for its pelvic mesh devices.

The court concluded that although 510(k) clearance typically demonstrates substantial equivalence rather than safety and efficacy, it was important in that case because plaintiffs argued Bard’s failure to conduct clinical trials was unreasonable. The court also held that New Jersey’s Products Liability Act does not automatically bar punitive damages merely because a device went through the 510(k) process.

April 2022: Woman Awarded $2.5 Million in Lawsuit Against Coloplast

A woman was awarded $2.5 million in a lawsuit against Coloplast after injuries from a pelvic mesh implant. The jury concluded that the mesh was defectively designed, that Coloplast failed to provide sufficient warnings to the surgeon, and that the company made negligent misrepresentations about the mesh’s safety.

May 2022: Delaware Court Partially Denies Summary Judgment in Pelvic Mesh Lawsuit

In Kaur v. Boston Scientific Corporation, the Superior Court of Delaware reviewed a products liability claim involving Boston Scientific’s Obtryx mesh product. The plaintiff alleged that the polypropylene surgical mesh implant used to treat stress urinary incontinence and pelvic organ prolapse caused her injuries.

The court granted the defendant’s motion for summary judgment in part and denied it in part, allowing certain claims to proceed.

Two reasons. First, only the strongest cases are being filed. Back when the MDLs were flooded with claims, weaker cases dragged settlement amounts down. Now, attorneys are filing individual lawsuits with plaintiffs who have clear evidence of harm, revision surgeries, and serious long-term injuries.

Second, an individual case means the plaintiff is treated as an individual. Her damages, pain, limitations, and medical history are evaluated on their own facts.

Strong current vaginal mesh lawsuits may settle in the $150,000 to $900,000 range, with some cases going higher depending on the severity of injury, number of surgeries, product identification, permanent symptoms, and impact on daily life. Catastrophic injury cases can have much higher trial value.

Studies have raised serious concerns that polypropylene mesh can degrade, oxidize, crack, and shed particles after implantation. Plaintiffs argue that this degradation contributes to chronic inflammation, pain, erosion, and tissue damage, and that manufacturers failed to adequately warn doctors and patients about these risks.

For many women, it may not be too late to file a claim, even though the original federal MDLs have closed. The key question is when the statute of limitations began to run. In many states, the clock may not start when the mesh was implanted. It may start when the woman discovered, or reasonably should have discovered, that her complications were linked to the mesh.

If you had a revision surgery in the last few years, or only recently learned that your pain, infections, erosion, or organ damage may be tied to your vaginal mesh implant, your claim may still be viable. Do not assume you are out of time without talking to a lawyer first.

Boston Scientific is still being sued despite previously settling large numbers of mesh lawsuits. New cases are being filed involving products such as Obtryx, Advantage Fit, and Uphold Lite. Plaintiffs allege these meshes were not safe for long-term implantation and that Boston Scientific failed to adequately warn doctors and patients about the risks.

Yes. TVT mesh, or tension-free vaginal tape, is a type of transvaginal mesh sling commonly used to treat stress urinary incontinence. TVT mesh lawsuits are part of the broader vaginal mesh litigation because the same polypropylene material and design issues can cause erosion, chronic pain, and the need for revision surgery.

The biggest mistake is assuming they do not have a case. Many women do not realize their symptoms may be linked to mesh degradation, erosion, contraction, or chronic inflammation. Others think they waited too long when the statute of limitations may still be open under the discovery rule. Talk to a vaginal mesh lawyer before assuming you are out of luck.

The first settlements were often bulk MDL settlements where thousands of claims were grouped together. That meant stronger cases were often averaged with weaker cases, lowering individual payouts. The strategy is different now. Stronger cases are being filed individually, which can lead to higher settlement values.

In 2019, the FDA ordered manufacturers to stop selling transvaginal mesh products for pelvic organ prolapse repair. Mesh for stress urinary incontinence remains on the market, even though it often uses similar polypropylene material. Plaintiffs argue that the same long-term material problems can cause serious injuries in sling cases.

Symptoms like chronic pelvic pain, mesh erosion, painful intercourse, organ perforation, urinary problems, recurrent infections, and the need for revision surgery are major warning signs. The only way to confirm the product and medical timeline is through medical records, but if you are experiencing these issues, you should talk to a lawyer.

Not always. But the strongest cases usually involve revision surgery, removal surgery, erosion, contraction, organ involvement, or a clear medical recommendation that the mesh should be revised or removed.

Yes. Some manufacturers are still resolving cases privately. These settlements may not be announced publicly because defendants do not want to encourage more filings or draw attention to continuing litigation risk.

Get your medical records. Your case depends on proof of implantation, product identification, complications, revision surgery, and the timeline connecting your symptoms to the mesh. A lawyer can help obtain the records, but the case starts with the medical proof.